RENAL AND BONE SAFETY OF TENOFOVIR ALAFENAMIDE VS TENOFOVIR DISOPROXIL FUMARATE

被引：0
|
作者：
Post, Frank [1 ]
Sax, Paul [2 ]
Saag, Michael [3 ]
Yin, Michael [4 ]
Oka, Shinichi [5 ]
Koenig, Ellen [6 ]
Trottier, Benoit [7 ]
Andrade, Jaime [8 ]
Cao, Huyen [9 ]
Fordyce, Marshall [9 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Alabama, Tuscaloosa, AL 35487 USA
[4] Columbia Univ, New York, NY USA
[5] Int Med Ctr Japan, Tokyo, Japan
[6] Dominican Inst Virol Studies, Santo Domingo, Japan
[7] Clin Med Actuel Montreal, Montreal, Dominican Rep
[8] Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico
[9] Gilead Sci Inc, Foster City, Mexico
来源：
SEXUALLY TRANSMITTED INFECTIONS | 2015年 / 91卷
关键词：
D O I：
10.1136/sextrans-2015-052126.142
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P99
引用
收藏
页码：A48 / +
页数：2
相关论文
共 50 条
  • [1] Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
    Gupta, Samir K.
    Post, Frank A.
    Arribas, Jose R.
    Eron, Joseph J., Jr.
    Wohl, David A.
    Clarke, Amanda E.
    Sax, Paul E.
    Stellbrink, Hans-Juergen
    Esser, Stefan
    Pozniak, Anton L.
    Podzamczer, Daniel
    Waters, Laura
    Orkin, Chloe
    Rockstroh, Juergen K.
    Mudrikova, Tatiana
    Negredo, Eugenia
    Elion, Richard A.
    Guo, Susan
    Zhong, Lijie
    Carter, Christoph
    Martin, Hal
    Brainard, Diana
    SenGupta, Devi
    Das, Moupali
    AIDS, 2019, 33 (09) : 1455 - 1465
  • [2] Tenofovir alafenamide versus tenofovir disoproxil fumarate is there a true difference in safety?
    Pepperrell, T.
    Hughes, S.
    Gotham, D.
    Pozniak, A.
    Boffito, M.
    Pilkington, V.
    Hill, A.
    HIV MEDICINE, 2019, 20 : 92 - 92
  • [3] Switching tenofovir disoproxil fumarate to tenofovir alafenamide not only bone and kidney
    Berger, F.
    Milinkovic, A.
    Arenas-Pinto, A.
    Mauss, S.
    ANTIVIRAL THERAPY, 2018, 23 : A48 - A48
  • [4] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Shao-Ming Chiu
    Kuo-Chin Chang
    Tsung-Hui Hu
    Chao-Hung Hung
    Jing-Houng Wang
    Sheng-Nan Lu
    Chien-Hung Chen
    Digestive Diseases and Sciences, 2023, 68 : 665 - 675
  • [5] Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate
    Liang, Lilian Yan
    Yip, Terry Cheuk-Fung
    Lai, Jimmy Che-To
    Lam, Amy Shuk-Man
    Tse, Yee-Kit
    Hui, Vicki Wing-Ki
    Chan, Henry Lik-Yuen
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (09) : 4440 - 4448
  • [6] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Chiu, Shao-Ming
    Chang, Kuo-Chin
    Hu, Tsung-Hui
    Hung, Chao-Hung
    Wang, Jing-Houng
    Lu, Sheng-Nan
    Chen, Chien-Hung
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (02) : 665 - 675
  • [7] Renal safety of tenofovir disoproxil fumarate
    Sax, Paul E.
    Gallant, Joel E.
    Klotman, Paul E.
    AIDS READER, 2007, 17 (02): : 90 - +
  • [8] Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill, A.
    Hughes, S.
    Pozniak, A.
    HIV MEDICINE, 2018, 19 : S30 - S30
  • [9] Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill, Andrew
    Hughes, Sophie L.
    Gotham, Dzintars
    Pozniak, Anton L.
    JOURNAL OF VIRUS ERADICATION, 2018, 4 (02) : 72 - 79
  • [10] Safety of tenofovir alafenamide (TAF) in patients with a history of proximal renal tubulopathy on tenofovir disoproxil fumarate (TDF)
    Hamzah, L.
    Jones, R.
    Bailey, A.
    Williams, D.
    Johnson, M.
    Ibrahim, F.
    Musso, C.
    Burling, K.
    Campbell, L.
    Post, F.
    HIV MEDICINE, 2019, 20 : 8 - 9
12345